Osmotica Pharmaceutical announced that the FDA has approved Osmolex ER (amantadine HCl extended release), for the treatment of Parkinson's disease...
Supernus Pharmaceuticals Inc, and Adamas Pharmaceuticals, Inc., announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an aggregate of approximately $400 million), payable at closing plus two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (or an aggregate of approximately $50 million), for a total consideration of $9.10 per share in cash (or an aggregate of approximately $450 million).
Egalet Corporation has announced that the FDA has approved Arymo ER (morphine sulfate) extended-release (ER) tablets C-II for the management...
Endo International plc continues to believe in the safety, efficacy, and favorable benefit-risk profile of Opana ER (oxymorphone hydrochloride extended...
Egalet Corporation announced that the FDA has accepted the new drug application (NDA) for Arymo ER (morphine sulfate) extended-release tablets....
Teva Pharmaceutical has announced the FDA approved Vantrela ER (hydrocodone bitartrate) extended-release tablets [CII] formulated with Teva’s proprietary abuse deterrence...
Collegium Pharmaceutical announced the publication of results from the Phase III clinical trial of Xtampza ER (oxycodone extended-release capsules). The...
Neos Therapeutics, Inc. announced that the FDA has approved Adzenys ER (amphetamine) Extended-Release Oral Suspension. Neos Therapeutics is the only...
Pfizer Inc. has announced that the FDA has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral...
Remoxy ER has a thick, sticky, high-viscosity capsule formulation designed to deter unapproved routes of drug administration, such as injection,...